Coherus BioSciences Inc. News
Regeneron's Eylea Win Leaves an Elephant in the Room
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Biosimilars Are Saving America $1 Billion Per Month
Competitive drug prices are great for consumers. Turns out, they're good for industry, too.
FDA Approves Coherus' Version of Abbvie's Humira, Best-Selling Drug in the U.S.
Coherus was cleared by the FDA for a drug that's similar to AbbVie's Humira. Coherus plans to launch the psoriasis treatment in July 2023.
Five Below, Splunk, Snap: 'Mad Money' Lightning Round
Jim Cramer weighs in on Five Below, Splunk, Snap, Crown Castle, Square, 3D Systems, Dana, Alibaba, Coherus Biosciences.
Five Rules For This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
Even with Monday's sharp reversal, Jim Cramer says he still likes this market.
Illumina's Singapore Tax Holiday is About to Expire
The DNA sequencing giant generated over 10% of its diluted earnings per share in 2021 from a tax holiday.
Oil Volatility Returns, Pushing Gasoline Prices Higher
The 14-week decline in gasoline prices ended while two million people in Florida are still without power.
New Electric Vehicle Beats Tesla When it Comes to the Environment
A new EV would radically change how cars are made and that could be a threat to the market leader.
McDonald's Menu Adds a (Very) New Take on an Old Favorite
The fast-food giant has been hesitant to make changes like this, but Wendy's bold move may have forced it to.